Sanofi-Aventis said today it lost a patent infringement case against two generic drug makers involving its top-selling product, the blockbuster bloodthinner Lovenox. Amphastar Pharmaceuticals and Teva ...
LONDON, June 5 (Reuters) - Doctors in Europe can continue to use Sanofi-Aventis SA's heparin medicine Lovenox, despite low levels of contamination found in some batches of the product, the European ...
Unlike unfractionated heparin (UFH), the low-molecular-weight heparin enoxaparin (Lovenox) is excreted mainly by the kidneys. To determine whether this characteristic heightens bleeding risk in ...
In an earlier version of this article, we inaccurately described the change to the Lovenox (enoxaparin) prescribing information. The revisions to the prescribing information regarding prosthetic heart ...
Lovenox (enoxaparin) is a prescription drug used to prevent or treat certain types of blood clots. Lovenox’s cost may depend on factors such as your dosage, whether you have health insurance, and how ...
Sanofi-Aventis has won FDA priority review for a new indication for its blockbuster blood thinner Lovenox.The FDA will review Lovenox for treatment of patients suffering acute ST-segment elevation ...
Pharma Eliquis fails to beat Lovenox at clot-fighting after surgery By Tracy Staton Nov 14, 2011 12:25pm Pharma ...
Sanofi’s big-selling blood thinner Lovenox has long faced generic competition in the U.S., but now rival generics makers are squashing long-running lawsuits over their own versions of the drug.
LONDON, July 8 (Reuters) - Bayer AG's experimental pill rivaroxaban is significantly more effective than standard injections of Lovenox in preventing blood clots after knee surgery, researchers said ...
GlaxoSmithKline is upping the ante in its bid to win market share from Sanofi-Aventis’ number one clotbusting drug, Lovenox (enoxaparin), and yesterday unveiled data at the European Society of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback